Previous 10 | Next 10 |
2024-02-14 08:38:21 ET More on Pre-market losers & stocks. Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Esports Entertainment announces 1-for-400 reverse stock split Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals His...
2024-02-13 08:37:05 ET More on Candel, Edgewise, etc. Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects Krystal Biotech added to Evercore’s Tactical Outperform list on...
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Adm...
Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate cancer Focusing on strategic key value drivers and catalysts, as a follow up to positive init...
2023-12-14 08:23:30 ET More on Pre-market losers & stocks. Cepton, Inc. (CPTN) Q3 2023 Earnings Call Transcript Shattuck Labs, Inc. (STTK) Q3 2023 Earnings Call Transcript Shattuck Labs, Inc. 2023 Q3 - Results - Earnings Call Presentation Shattuck Labs st...
2023-12-12 09:59:18 ET DENVER, Colo., Dec. 12, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Aditxt Inc (NASDAQ: ADTX), C4 Therapeutics Inc. (NASDAQ: CCCC), IN8bio Inc. (NASDAQ: INAB), Candel Therapeuti...
2023-12-12 09:28:15 ET More on Candel Therapeutics Candel to cut 50% of staff in portfolio reorganization Candel Therapeutics jumps on Phase 2 data for cancer drug Seeking Alpha’s Quant Rating on Candel Therapeutics Historical earnings data for Candel ...
NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Adm...
2023-12-08 09:30:00 ET December 8, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Life Sciences, Fintech and Defense. Today's stocks have been added to our lists of fre...
2023-11-28 10:35:11 ET More on Candel Therapeutics Candel Therapeutics jumps on Phase 2 data for cancer drug Seeking Alpha’s Quant Rating on Candel Therapeutics Historical earnings data for Candel Therapeutics Financial information for Candel Therapeut...
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
Candel Therapeutics Inc. Website:
2024-07-16 20:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 01:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Pete...